Marketing Update. (a) Following receipt of an Approval Letter from the FDA for the Product or an equivalent letter from a Competent Authority, Fujisawa shall provide Cardiome on a semi-annual basis during the Term (every February 1 and August 1) with reports in reasonable detail describing Fujisawa’s material marketing efforts with respect to the Product in the Territory during the immediately preceding six (6) month period and all existing marketing plans for the Product for the immediately following twenty-four (24) month period. Such reports and plans will be provided to Cardiome commencing ninety (90) days after receipt of such Approval Letter with the next such report to be provided on the February 1 or August 1 deadline next following the initial report (provided that if this would result in the second report being provided within less than six (6) months, Fujisawa may deliver the second report at the next applicable deadline). The Parties shall meet once annually to review all such reports. The Chief Executive Officer, or the designee of the Chief Executive Officer, of Cardiome and a senior marketing executive of Fujisawa shall attend such meeting.
Marketing Update. Following receipt of an Approval Letter from the FDA for the Product, Spring Bank shall provide BioHEP on a semi-annual basis during the Term (every February 1 and August 1) with reports in reasonable detail describing Spring Bank’s material marketing efforts with respect to the Product in the Territory during the immediately preceding six (6) month period and forecasts and plans for such efforts for the immediately following twelve (12) month period. Such reports will be provided to BioHEP commencing ninety (90) days after receipt of such Approval Letter with the next such report to be provided on the February 1 or August 1 deadline next following the initial report (provided that if this would result in the second report being provided within less than six (6) months, Spring Bank may deliver the second report at the next applicable deadline). The Parties shall meet once annually to review all such reports. Spring Bank agrees to consider BioHEP’s input and comments that BioHEP may provide related to any such report for any applicable period.
Marketing Update. A. December and January Marketing Report. Xx. Xxxxx presented the December and January Marketing Report.
Marketing Update. Following receipt of an Approval Letter from the FDA for the Product or an equivalent letter from a Competent Authority, Strata shall provide Micrologix on an annual basis during the Term, through the JDMC or otherwise, with reports in reasonable detail describing Strata's material marketing efforts with respect to the Product in the Territory during the preceding year and forecasts and plans for such efforts for the following year. Strata agrees to consider Micrologix's input and comments that Micrologix may provide related to any such report for any applicable period; provided, however, Strata shall have the right to either accept or reject such input and/or comments in whole or in part in Strata's sole discretion for any reason whatsoever, and Strata shall have the final and sole right and responsibility and decision-making authority for all matters related to any such report(s).
Marketing Update. (a) Following receipt of an Approval Letter from the FDA for the Product or an equivalent letter from a Competent Authority, Strata shall provide Micrologix on an annual basis during the Term, through the JDMC or otherwise, with reports in reasonable detail describing Strata’s material marketing efforts with respect to the Product in the Territory during the preceding year and forecasts and plans for such efforts for the following year.
Marketing Update. (a) Following receipt of an Approval Letter from the FDA for the Product or an equivalent letter from a Competent Authority, Strata shall provide Micrologix on *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. an annual basis during the Term, through the JDMC or otherwise, with reports in reasonable detail describing Strata’s material marketing efforts with respect to the Product in the Territory during the preceding year and forecasts and plans for such efforts for the following year.
Marketing Update. Following receipt of an Approval Letter from the FDA for the Product, Spring Bank shall provide Micrologix on a semi-annual basis during the Term (every February 1 and August 1) with reports in reasonable detail describing Spring Bank’s material marketing efforts with respect to the Product in the Territory during the immediately preceding six (6) month period and forecasts and plans for such efforts for the immediately following twelve (12) month period. Such reports will be provided to Micrologix commencing ninety (90) days after receipt of such Approval Letter with the next such report to be provided on the February 1 or August 1 deadline next following the initial report (provided that if this would result in the second report being provided within less than six (6) months, Spring Bank may deliver the second report at the next applicable deadline). The Parties shall meet once annually to review all such reports. Spring Bank agrees to consider Micrologix’s input and comments that Micrologix may provide related to any such report for any applicable period.
Marketing Update. 5.9.1 Following receipt of a Marketing Authorization for a Licensed Product, the Company shall provide Licensor on an annual basis during the Term with reports in reasonable detail describing the Company’s material marketing efforts with respect to such Licensed Product in the Territory during the preceding year and forecasts and plans for such efforts for the following year.
